These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16491719)

  • 21. Photo quiz: A 36-year-old with recurrent conjunctivitis.
    Burd EM; Sharp SE
    J Clin Microbiol; 2012 Feb; 50(2):215, 543. PubMed ID: 22268126
    [No Abstract]   [Full Text] [Related]  

  • 22. [Moxifloxacin (Kanavig), ophthalmic administration].
    J Pharm Belg; 2012 Jun; (2):41-2. PubMed ID: 22978015
    [No Abstract]   [Full Text] [Related]  

  • 23. Evidence-based review of moxifloxacin.
    O'Brien TP
    Int Ophthalmol Clin; 2006; 46(4):61-72. PubMed ID: 17060792
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis.
    Ohnsman C; Ritterband D; O'Brien T; Girgis D; Kabat A
    Curr Med Res Opin; 2007 Sep; 23(9):2241-9. PubMed ID: 17688706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
    Schlech BA; Blondeau J
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S64-7. PubMed ID: 16257312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of moxifloxacin in the treatment of secondary peritonitis].
    Iakovlev SV; Ramishvili VSh; Nazarov VV; Eremina LV
    Antibiot Khimioter; 2006; 51(5):3-10. PubMed ID: 17310784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Moxifloxacin, a novel extended spectrum fluoroquinolone in the treatment of severe infectious inflammatory diseases].
    Svetukhin AM; Blatun LA; Ukhin SA
    Antibiot Khimioter; 2005; 50(2-3):64-72. PubMed ID: 16308942
    [No Abstract]   [Full Text] [Related]  

  • 28. Tsukamurella: an emerging opportunistic ocular pathogen.
    Almeida DR; Miller D; Alfonso EC
    Can J Ophthalmol; 2010 Jun; 45(3):290-3. PubMed ID: 20628423
    [No Abstract]   [Full Text] [Related]  

  • 29. Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?
    Mohapatra PR
    Am J Respir Crit Care Med; 2009 Oct; 180(7):686; author reply 686-7. PubMed ID: 19762595
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
    Hoepelman I
    Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New indications for novel fluoroquinolones: moxifloxacin in the treatment of nosocomial infections].
    Beloborodova NV; Popov DA; Vostrikova TIu; Bachinskaia EN; Kuznetsova ST
    Antibiot Khimioter; 2009; 54(1-2):25-6, 28-30. PubMed ID: 19499714
    [No Abstract]   [Full Text] [Related]  

  • 33. A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.
    Son SW; Kim HJ; Seo JW
    Korean J Ophthalmol; 2011 Oct; 25(5):349-51. PubMed ID: 21976944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
    Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
    Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
    Schlech BA; Alfonso E
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eikenella corrodens as a causative agent for neonatal conjunctivitis.
    Chhabra MS; Motley WW; Mortensen JE
    J AAPOS; 2008 Oct; 12(5):524-5. PubMed ID: 18562227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unilateral conjunctival ulcer due to Stenotrophomonas maltophilia infection.
    Mahendradas P; Avadhani K; Anandula V; Shetty R
    Indian J Ophthalmol; 2012; 60(2):134-6. PubMed ID: 22446910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application.
    Ta CN; Chan I; Dhatt HS; Paterno J; Fisher E; Singh K; Montague A; Egbert PR; Cockerham G; Kaspar HM
    J Ocul Pharmacol Ther; 2008 Aug; 24(4):427-31. PubMed ID: 18665815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
    Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.